| Name | Title | Contact Details |
|---|
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health for US, European and other world markets.
VintaBio is a life sciences company that specializes in customized process development, GMP manufacturing, and quality control services for cell and gene therapies.
As America’s largest independent cardiac care practice, CCP is home to the most experienced cardiologists in the Philadelphia region.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.
Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow`s pipeline is led by SPI-62 in Phase 2 clinical development.